Elf score interpretation. The utility of the ELF score has been demonstrated primarily in Weste...
Elf score interpretation. The utility of the ELF score has been demonstrated primarily in Western countries, but whether it is useful in areas The Enhanced Liver Fibrosis (ELF™) blood test is a simple, accurate, non-invasive test that provides a simple, unitless numeric score that is generated via an algorithm for use in advanced liver fibrosis. However, there is a need for independent validation of the ELF score with regard to validated reference val-ues, influencing factors and suitable cut-off values. Complications include progression to cirrhosis, end stage liver disease and hepatocellular carcinoma. A worrying trend is the increasing numbers of cases of cirrhosis due to FIB-4 1. Recommend referral to Metabolic Hepatology Clinic. The ELF score consisting of single markers of hepatic matrix metabolism is one of the first commercially available serum mul-timarker fibrosis tests. Find out about scoring systems for cirrhosis. The Enhanced Liver Fibrosis (ELF™) test is a noninvasive blood (serum) lab test, which combines three direct ECM biomarkers: hyaluronic acid (HA), procollagen III aminoterminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1), into a validated composite score. 5 Low risk for advanced liver fibrosis. The ELF Score is recommended by AACE guidelines,6 as its measurements have proven valuable for identifying patients with advanced fibrosis (F3 or F4) at risk of progressing to cirrhosis and liver-related events. Fibrosis means scarring of the liver. Interpretation of ELF Test Results According to AASLD guidance, based on expert opinion, an ELF score ≥7. These values are summarized into a single score, which can be compared to different thresholds for diagnosis. It is a stage of long-term liver disease. Higher ELF scores indicate a greater risk of liver fibrosis progression. The ELF score consisting of single markers of hepatic matrix metabolism is one of the first commercially available serum multimarker fibrosis tests. The utility of the ELF score has been demonstrated primarily in Western countries, but whether it is useful in areas Jul 18, 2025 · The Enhanced Liver Fibrosis (ELF) score is a validated serum biomarker panel that measures three matrix turnover proteins to accurately assess liver fibrosis Pretest risk refers to the likelihood of disease progression in the overall intended use population without considering the ELF Score. 7 during secondary risk assessment suggests the need for Background and aims: The enhanced liver fibrosis (ELF) score is a blood test that combines three markers linked to liver fibrosis. Check your ELF Score Liver Calculator results to assess liver fibrosis, track liver health, and understand your risk with accurate scoring. The ELF . The Enhanced Liver Fibrosis score (ELF score) Liver fibrosis can result from a number of pathological processes, the most common being chronic hepatitis B & C, alcohol abuse, and non-alcohol-related steatohepatitis (NASH). But if the damage continues it can cause cirrhosis. Interpretive information The ELF score indicates the risk of disease progression to cirrhosis or liver-related events based on established thresholds (Table). Background and aims: The enhanced liver fibrosis (ELF) score is a blood test that combines three markers linked to liver fibrosis. Advanced liver fibrosis risk scores The National Institute for Health and Care Excellence (NICE) recommends considering the use of the Enhanced Liver Fibrosis (ELF) test to assess the risk of advanced liver fibrosis in people with suspected non-alcoholic fatty liver disease (NAFLD) [NICE, 2016]. Nov 8, 2025 · Find out what is the normal range for the ELF test and learn how to interpret your score. ELF ≥9. Results should always be interpreted in conjunction with the patient’s medical history, clinical presentation, and other findings. 10 Table. 5 High risk for advanced liver fibrosis. Treat metabolic risk factors and if there is ongoing risk suggest repeating test in 3 years. A liver with fibrosis can still do all its usual jobs. Find out more about fibrosis. Nov 17, 2022 · ELF score defines a three-marker fibrosis test (TIMP-1, PIIINP, HA) for assessing advanced fibrosis in NAFLD, guiding referrals and monitoring intervals. It is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to nonalcoholic . However, there is a need for independent validation of the ELF score with regard to validated reference values, influencing factors and suitable cut-off values. Fibrosis scoring systems (FIB-4 and ELF) This page includes information about the ELF and Fib-4 fibrosis scoring systems. The performance of the ELF Test has been well-established in the scientific literature, and ease of testing and interpretation support routine clinical use. 3 - 2. The ELF score is not for use in the diagnosis of NASH, the staging of fibrosis, the serial monitoring of disease progression, or the monitoring of effects of therapeutic products. 67 (Indeterminate) ELF <9. It is not a comprehensive pathway for the investigation of abnormal LFTs. The ELF™ score helps clinicians and researchers assess fibrosis severity and risk in metabolic and The three direct markers of the ELF Test are complementary and, when combined into an ELF score, provide information that is prognostic for progression to cirrhosis and liver-related events. Retest ELF every 3 years Refer to hepatology clinic See information boxes on following page for additional information. The ELF test is a panel of three biomarkers: type III procollagen peptide (PIIINP), hyaluronic acid (HA), and tissue inhibitor of metalloproteinase-1 (TIMP1). Clinical Significance Enhanced Liver Fibrosis (ELF) Score - The Enhanced Liver Fibrosis (ELF) score predicts progression to cirrhosis and liver-related events in patients with advanced fibrosis due to NASH. PLEASE NOTE: This pathway is a guide for the use of the ELF Score in the assessment of advanced liver fibrosis in patients with NAFLD. igvgczwgjfubhmeklljxpbdosfdbrqbjnzkddkrrvmlyqe